select semaglutide trial in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical Semaglutide 2.4 mg reduces risk

doi: 10.1016/j.neubiorev.2015.11.005 66 MooreK.MadularuD.IriahS.YeeJ

But you may want to see your healthcare provider if your belching is: Ongoing and not improving with dietary or lifestyle changes Accompanied by severe nausea, vomiting, or abdominal pain Affecting your ability to eat, sleep, or socialize If you experience any of these situations, contact your healthcare provider

Some patients may benefit from combination products such as insulin degludec/liraglutide (Xultophy) or insulin glargine/lixisenatide (Suliqua), which combine basal insulin with a GLP-1 agonist

Oral Wegovy (Semaglutide Pill) For those who prefer an oral option, Oral Wegovy provides the same GLP-1 mechanism without needles